Possibilities of combined use of peptides in the treatment of post-stroke asthenia

Among the various syndromes in the post-stroke period, asthenic disorder plays an important role, the presence of which is associated with unfavourable course of the disease. Post-stroke fatigue is, on the one hand, the result of organic brain lesions and, on the other hand, a person's emotional reaction to the clinical manifestations of stroke and its consequences. Affective and cognitive disorders are common comorbidities of fatigue after stroke. To correct asthenic manifestations, a holistic approach with pharmacological, physical, and psychological treatments is used. The main components in the pathogenesis of fatigue are hypoxia and energy imbalance, so it seems reasonable to include in the complex therapy of post-stroke fatigue the drug Cytochrome C, which is a key peptide of the mitochondrial respiratory chain. Considering the frequent combination with cognitive disorders of different modality, the use of bovine cerebral cortex polypeptides in patients with post-stroke fatigue is pathogenetically reasonable. Inclusion of drugs with a complex mechanism of action on hypoxia, oxidative stress, energy deficiency, and neuroplasticity processes in the therapeutic algorithm may increase the effectiveness of treatment.